You have 9 free searches left this month | to do more

ixazomib

Ixazomib is a drug used to treat Multiple Myeloma, Lymphoma, Advanced Solid Tumors, and other conditions. Ixazomib is being actively studied in 43 studies and prior, has been studied in 26.

Top SponsorsTop SitesTop Investigators
Millennium Pharmaceuticals, Inc.Dana Farber Cancer InstituteAjai Chari
TakedaMemorial Sloan Kettering Cancer CenterAjay Nooka
M.D. Anderson Cancer CenterMayo ClinicAndrew Yee, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Recruiting
  • Mantle Cell Lymphoma
  • Ixazomib
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
2022-03-31
Mar 31, 2022
D
Active, not recruiting
  • Smoldering Multiple Myeloma
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-03-15
Mar 15, 2022
M
Active, not recruiting
  • Solid Tumors
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-02-09
Feb 9, 2022
P
Recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-02-28
Feb 28, 2022
E
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
2022-01-05
Jan 5, 2022
E
Active, not recruiting
  • Mantle Cell Lymphoma
  • Ixazomib
  • Rituximab
  • Atlanta, Georgia
  • +1 more
2021-10-26
Oct 26, 2021
E
Completed
  • Glioblastoma
  • Ixazomib
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
2021-03-02
Mar 2, 2021
T
Completed
  • Relapsed and/or Refractory Multiple Myeloma
  • Ixazomib
  • +2 more
  • Tokyo, Japan
    Takeda Selected Site
2021-06-03
Jun 3, 2021
P
Active, not recruiting
  • Mantle-Cell Lymphoma
  • Atlanta, Georgia
  • +13 more
2022-03-31
Mar 31, 2022
H
Terminated
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
2022-03-15
Mar 15, 2022
M
Completed
  • Myeloid Hematologic Malignancy
  • Lymphoid Hematologic Malignancy
  • Ixazomib
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-09-03
Sep 3, 2021
M
Recruiting
  • AL Amyloidosis
  • Boston, Massachusetts
  • +7 more
2022-01-21
Jan 21, 2022
B
Active, not recruiting
  • B Cell Lymphoma
  • Lymphoma
  • Ixazomib
  • +2 more
  • Cleveland, Ohio
  • +1 more
2022-03-03
Mar 3, 2022
P
Recruiting
  • Multiple Myeloma
  • Beijing, Beijing, China
    PekingUMCH
2021-11-30
Nov 30, 2021
M
Recruiting
  • Metastatic Kidney Medullary Carcinoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-07-14
Jul 14, 2021
O
Recruiting
  • Newly Diagnosed Multiple Myeloma
  • West Hollywood, California
    James R Berenson, MD, Inc.
2020-10-23
Oct 23, 2020
W
Recruiting
  • Systemic Sclerosis
  • +18 more
  • Ixazomib
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
2021-04-30
Apr 30, 2021
R
Active, not recruiting
  • Multiple Myeloma
  • Ixazomib
  • +2 more
  • Helsinki, Finland
  • +25 more
2022-03-14
Mar 14, 2022
T
Active, not recruiting
  • Multiple Myeloma
  • Ixazomib
  • Odense, Denmark
    Odense University Hospital
2021-11-18
Nov 18, 2021
F
Recruiting
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Ixazomib
  • +3 more
  • Badalona, Spain
  • +7 more
2021-01-08
Jan 8, 2021
R
Active, not recruiting
  • Lymphoma, T-Cell, Peripheral
  • Chicago, Illinois
  • +6 more
2021-01-15
Jan 15, 2021
N
Completed
  • Multiple Myeloma
  • Allogeneic HSCT
  • +5 more
  • Birmingham, Alabama
  • +14 more
2022-01-25
Jan 25, 2022